Momenta Pharmaceuticals (MNTA) Is Today's Perilous Reversal Stock
Trade-Ideas LLC identified
(
) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Momenta Pharmaceuticals as such a stock due to the following factors:
- MNTA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.2 million.
- MNTA has traded 55,505 shares today.
- MNTA is down 3.4% today.
- MNTA was up 5.1% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in MNTA with the Ticky from Trade-Ideas. See the FREE profile for MNTA NOW at Trade-Ideas
More details on MNTA:
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently there are 4 analysts that rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.
The average volume for Momenta Pharmaceuticals has been 740,400 shares per day over the past 30 days. Momenta has a market cap of $1.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.39 and a short float of 14.6% with 6.59 days to cover. Shares are up 48.4% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Momenta Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive.
Highlights from the ratings report include:
- The revenue growth greatly exceeded the industry average of 10.4%. Since the same quarter one year prior, revenues rose by 47.8%. Growth in the company's revenue appears to have helped boost the earnings per share.
- MNTA has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, MOMENTA PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income has decreased by 3.3% when compared to the same quarter one year ago, dropping from -$29.10 million to -$30.05 million.
- You can view the full Momenta Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.